{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:43:09Z","timestamp":1792856589427,"version":"4.5.0"},"reference-count":163,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2025ZZBS03"],"award-info":[{"award-number":["2025ZZBS03"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.apjo.2026.100305","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:04:40Z","timestamp":1773968680000},"page":"100305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel drug development for geographic atrophy"],"prefix":"10.1016","volume":"15","author":[{"given":"Hiu Ying Enne","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-4342","authenticated-orcid":false,"given":"Jingfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8471-2766","authenticated-orcid":false,"given":"Nishant V.","family":"Radke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoju","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-2838","authenticated-orcid":false,"given":"Xiangsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7693-522X","authenticated-orcid":false,"given":"Victor","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.apjo.2026.100305_bib1","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.clinthera.2021.08.011","article-title":"Global burden of dry age-related macular degeneration: a targeted literature review","volume":"43","author":"Schultz","year":"2021","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib3","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.apjo.2026.100305_bib4","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2024.12.018","article-title":"Age-related macular degeneration preferred practice pattern\u00ae","volume":"132","author":"Vemulakonda","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100305_bib5","unstructured":"Facts & Figures | Macular Degeneration | BrightFocus Foundation. Accessed December 26, 2025. \u3008https:\/\/www.brightfocus.org\/macular\/facts-figures\/\u3009."},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100207","article-title":"Geographic atrophy: understanding the relationship between structure and function","volume":"14","author":"Huang","year":"2025","journal-title":"Asia Pac J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2023.100003","article-title":"Genetic associations of central serous chorioretinopathy subtypes, neovascular age-related macular degeneration, and polypoidal choroidal vasculopathy","volume":"13","author":"Chen","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100305_bib8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/genes13071233","article-title":"Molecular genetic mechanisms in age-related macular degeneration","volume":"13","author":"Shughoury","year":"2022","journal-title":"Genes"},{"issue":"9","key":"10.1016\/j.apjo.2026.100305_bib9","article-title":"Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration","volume":"9","author":"Evans","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.apjo.2026.100305_bib10","doi-asserted-by":"crossref","unstructured":"Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015. doi:10.1001\/jama.2013.4997.","DOI":"10.1001\/jama.2013.4997"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41433-021-01765-x","article-title":"Complement cascade inhibition in geographic atrophy: a review","volume":"36","author":"Desai","year":"2022","journal-title":"Eye"},{"issue":"10","key":"10.1016\/j.apjo.2026.100305_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007418","article-title":"CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD","volume":"4","author":"Scholl","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.apjo.2026.100305_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102616","article-title":"Complement system modulation in age-related macular degeneration: navigating failures, building future successes","volume":"96","author":"Vienne-Jumeau","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.apjo.2026.100305_bib14","unstructured":"Alexion Pharmaceuticals, Inc. A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). clinicaltrials.gov; 2025. Accessed December 31, 2025. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05019521\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib15","unstructured":"Novartis Pharmaceuticals. A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-of-Concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-Related Macular Degeneration. clinicaltrials.gov; 2025. Accessed December 31, 2025. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05230537\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2019.04.001","article-title":"Retinal oximetry: metabolic imaging for diseases of the retina and brain","volume":"70","author":"Stef\u00e1nsson","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0039-6257(00)00140-5","article-title":"The role of oxidative stress in the pathogenesis of age-related macular degeneration","volume":"45","author":"Beatty","year":"2000","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/ijms22031296","article-title":"Age-related macular degeneration: role of oxidative stress and blood vessels","volume":"22","author":"Ruan","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apjo.2026.100305_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100858","article-title":"Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration","volume":"79","author":"Kaarniranta","year":"2020","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.apjo.2026.100305_bib20","article-title":"How does the macula protect itself from oxidative stress?","volume":"33","author":"Jt","year":"2012","journal-title":"Mol Asp Med"},{"issue":"5","key":"10.1016\/j.apjo.2026.100305_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cellsig.2012.01.008","article-title":"Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling","volume":"24","author":"Ray","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.apjo.2026.100305_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/690243","article-title":"NLRP3 inflammasome: activation and regulation in age-related macular degeneration","volume":"2015","author":"Gao","year":"2015","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.apjo.2026.100305_bib23","article-title":"Small Hyperreflective Retinal Foci as in vivo imaging feature of resident microglia activation in geographic atrophy","volume":"248","author":"E P","year":"2024","journal-title":"Exp eye Res"},{"key":"10.1016\/j.apjo.2026.100305_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101263","article-title":"Targeting inflammasomes and pyroptosis in retinal diseases-molecular mechanisms and future perspectives","volume":"101","author":"Sun","year":"2024","journal-title":"Prog Retin Eye Res"},{"issue":"48","key":"10.1016\/j.apjo.2026.100305_bib25","doi-asserted-by":"crossref","first-page":"E11359","DOI":"10.1073\/pnas.1807123115","article-title":"Permanent neuroglial remodeling of the retina following infiltration of CSF1R inhibition-resistant peripheral monocytes","volume":"115","author":"Paschalis","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000492886","article-title":"Oxidative stress is the principal contributor to inflammasome activation in retinal pigment epithelium cells with defunct proteasomes and autophagy","volume":"49","author":"Piippo","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"10.1016\/j.apjo.2026.100305_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.21887","article-title":"Amyloid \u03b2 induces NLRP3 inflammasome activation in retinal pigment epithelial cells via NADPH oxidase- and mitochondria-dependent ROS production","volume":"31","author":"Wang","year":"2017","journal-title":"J Biochem Mol Toxicol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1167\/iovs.12-10655","article-title":"NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration","volume":"54","author":"Tseng","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Pt B","key":"10.1016\/j.apjo.2026.100305_bib29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.arr.2015.09.002","article-title":"RPE necroptosis in response to oxidative stress and in AMD","volume":"24","author":"Hanus","year":"2015","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.apjo.2026.100305_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biochi.2018.07.010","article-title":"Fatty acids and oxidized lipoproteins contribute to autophagy and innate immunity responses upon the degeneration of retinal pigment epithelium and development of age-related macular degeneration","volume":"159","author":"Kaarniranta","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.apjo.2026.100305_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.preteyeres.2015.09.002","article-title":"Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration","volume":"51","author":"Ferrington","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"10.1016\/j.apjo.2026.100305_bib32","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00018-016-2147-8","article-title":"Inflammation and its role in age-related macular degeneration","volume":"73","author":"Kauppinen","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"10.1016\/j.apjo.2026.100305_bib33","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s10495-012-0750-1","article-title":"Enhanced apoptosis in retinal pigment epithelium under inflammatory stimuli and oxidative stress","volume":"17","author":"Wang","year":"2012","journal-title":"Apoptosis"},{"key":"10.1016\/j.apjo.2026.100305_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100858","article-title":"Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration","volume":"79","author":"Kaarniranta","year":"2020","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"10.1016\/j.apjo.2026.100305_bib35","first-page":"3041","article-title":"Inhibition of RPE lysosomal and antioxidant activity by the age pigment lipofuscin","volume":"42","author":"Shamsi","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.apjo.2026.100305_bib36","first-page":"1981","article-title":"The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells","volume":"41","author":"Sparrow","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.apjo.2026.100305_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/112067219800800401","article-title":"Age-related macular degeneration: review of pathogenesis","volume":"8","author":"Zarbin","year":"1998","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100305_bib38","article-title":"Oxidative stress and 4-hydroxy-2-nonenal (4-HNE): implications in the pathogenesis and treatment of aging-related diseases","volume":"2022","author":"Li","year":"2022","journal-title":"J Immunol Res"},{"key":"10.1016\/j.apjo.2026.100305_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.626842","article-title":"Dooming phagocyte responses: inflammatory effects of endogenous oxidized phospholipids","volume":"12","author":"Di Gioia","year":"2021","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib40","doi-asserted-by":"crossref","first-page":"E521","DOI":"10.1208\/aapsj080362","article-title":"Mitochondria-targeted peptide antioxidants: novel neuroprotective agents","volume":"8","author":"Szeto","year":"2006","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/antiox14020152","article-title":"Antioxidants in age-related macular degeneration: lights and shadows","volume":"14","author":"Parmar","year":"2025","journal-title":"Antioxidants"},{"issue":"9","key":"10.1016\/j.apjo.2026.100305_bib42","article-title":"Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration","volume":"9","author":"Evans","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/nu17020331","article-title":"Photoprotective effects of phytochemicals on blue light-induced retinal damage: current evidence and future perspectives","volume":"17","author":"Yeh","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.apjo.2026.100305_bib44","doi-asserted-by":"crossref","unstructured":"Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436. doi:10.1001\/archopht.119.10.1417.","DOI":"10.1001\/archopht.119.10.1417"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100628","article-title":"ReCLAIM-2: a randomized phase ii clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation","volume":"5","author":"Ehlers","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100086","article-title":"Phase 1 clinical trial of elamipretide in dry age-related macular degeneration and noncentral geographic atrophy: ReCLAIM NCGA study","volume":"2","author":"Mettu","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"12","key":"10.1016\/j.apjo.2026.100305_bib48","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1134\/S0006297908120018","article-title":"Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: synthesis and in vitro studies","volume":"73","author":"Antonenko","year":"2008","journal-title":"Biochemistry (Mosc"},{"issue":"10","key":"10.1016\/j.apjo.2026.100305_bib49","first-page":"1101","article-title":"Preventive and therapeutic effects of SkQ1-containing Visomitin eye drops against light-induced retinal degeneration","volume":"79","author":"Novikova","year":"2014","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antiox8010003","article-title":"Suppression of light-induced oxidative stress in the retina by mitochondria-targeted antioxidant","volume":"8","author":"Baksheeva","year":"2018","journal-title":"Antioxidants"},{"issue":"6","key":"10.1016\/j.apjo.2026.100305_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/antiox8060177","article-title":"Suppression of AMD-like pathology by mitochondria-targeted antioxidant SkQ1 is associated with a decrease in the accumulation of amyloid \u03b2 and in mTOR activity","volume":"8","author":"Muraleva","year":"2019","journal-title":"Antioxidants"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib52","first-page":"201","article-title":"Retinoprotective effect of SkQ1, visomitin eye drops, is associated with suppression of P38 MAPK and ERK1\/2 signaling pathways activity","volume":"89","author":"Muraleva","year":"2024","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.apjo.2026.100305_bib53","article-title":"Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration","volume":"12","author":"Yeong","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.apjo.2026.100305_bib54","article-title":"The NLRP3 inflammasome inhibitor OLT1177 attenuates retinal neovascularization and microglial inflammation with neuroprotective effects","volume":"170","author":"Wu","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib55","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ajpath.2019.10.011","article-title":"Effect of inhibition of colony-stimulating factor 1 receptor on choroidal neovascularization in mice","volume":"190","author":"Schwarzer","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apjo.2026.100305_bib56","unstructured":"Harp M.D. Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy | Ophthalmology Times - Clinical Insights for Eye Specialists. December 31, 2025. Accessed December 31, 2025. \u3008https:\/\/www.ophthalmologytimes.com\/view\/aviceda-reports-positive-phase-2b-siglec-results-for-avd-104-in-geographic-atrophy\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib57","unstructured":"Aviceda Therapeutics, Inc. A Single and Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration. clinicaltrials.gov; 2025. Accessed December 31, 2025. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05839041\u3009."},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12915-025-02198-8","article-title":"Dysregulated lipid metabolism in a retinal pigment epithelial cell model and serum of patients with age-related macular degeneration","volume":"23","author":"\u00c1lvarez-Barrios","year":"2025","journal-title":"BMC Biol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib59","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1194\/jlr.M300306-JLR200","article-title":"Regulated expression of apolipoprotein E by human retinal pigment epithelial cells","volume":"45","author":"Ishida","year":"2004","journal-title":"J Lipid Res"},{"issue":"22","key":"10.1016\/j.apjo.2026.100305_bib60","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1093\/hmg\/ddx319","article-title":"Retinal pigment epithelium cholesterol efflux mediated by the 18\u2009kDa translocator protein, TSPO, a potential target for treating age-related macular degeneration","volume":"26","author":"Biswas","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apjo.2026.100305_bib61","article-title":"Inc. A Phase 2\/3 Multicenter, Randomized, Double-Masked, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-Related Macular Degeneration","author":"Pharmaceuticals","year":"2025","journal-title":"Clin Gov"},{"key":"10.1016\/j.apjo.2026.100305_bib62","unstructured":"Belite Bio, Inc. PHase 3, Multicenter, RandOmized, Double-Masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study). clinicaltrials.gov; 2025. Accessed December 30, 2025. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05949593\u3009."},{"issue":"6","key":"10.1016\/j.apjo.2026.100305_bib63","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.preteyeres.2009.08.001","article-title":"Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins","volume":"28","author":"Curcio","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2026.100305_bib64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.preteyeres.2017.09.001","article-title":"Complement factor H in AMD: Bridging genetic associations and pathobiology","volume":"62","author":"Toomey","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"10.1016\/j.apjo.2026.100305_bib65","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1167\/iovs.10-5637","article-title":"Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial","volume":"51","author":"Wong","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"13","key":"10.1016\/j.apjo.2026.100305_bib66","first-page":"6416","article-title":"Topical OT-551 for treating geographic atrophy: phase ii results","volume":"51","author":"Sternberg","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.apjo.2026.100305_bib67","first-page":"3292","article-title":"Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa","volume":"43","author":"Tao","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.preteyeres.2011.11.005","article-title":"CNTF and retina","volume":"31","author":"Wen","year":"2012","journal-title":"Prog Retin Eye Res"},{"issue":"15","key":"10.1016\/j.apjo.2026.100305_bib69","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.apjo.2026.100305_bib70","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1167\/iovs.10-6418","article-title":"Complement deposition and microglial activation in the outer retina in light-induced retinopathy: inhibition by a 5-HT1A agonist","volume":"52","author":"Collier","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.apjo.2026.100305_bib71","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.ajo.2015.08.024","article-title":"Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration: the GATE study","volume":"160","author":"Jaffe","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib72","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/IAE.0000000000002789","article-title":"Phase 2 study of the safety and efficacy of brimonidine drug delivery system (BRIMO DDS) Generation 1 In patients with geographic atrophy secondary to age-related macular degeneration","volume":"41","author":"Kuppermann","year":"2021","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.apjo.2026.100305_bib73","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.oret.2023.03.001","article-title":"Randomized phase iib study of brimonidine drug delivery system generation 2 for geographic atrophy in age-related macular degeneration","volume":"7","author":"Freeman","year":"2023","journal-title":"Ophthalmol Retin"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib74","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/IAE.0b013e318265801d","article-title":"Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration","volume":"33","author":"Mata","year":"2013","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.apjo.2026.100305_bib75","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.ophtha.2018.03.059","article-title":"Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial","volume":"125","author":"Rosenfeld","year":"2018","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1016\/j.apjo.2026.100305_bib76","first-page":"4919","volume":"50","author":"Vogel","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"18","key":"10.1016\/j.apjo.2026.100305_bib77","doi-asserted-by":"crossref","first-page":"11830","DOI":"10.1073\/pnas.192203399","article-title":"The Alzheimer\u2019s A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration","volume":"99","author":"Johnson","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.apjo.2026.100305_bib78","unstructured":"Phase I., Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD) | IOVS | ARVO Journals. Accessed December 31, 2025. \u3008https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2149375\u3009."},{"issue":"10","key":"10.1016\/j.apjo.2026.100305_bib79","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.oret.2018.03.001","article-title":"A randomized phase 2 study of an anti-amyloid \u03b2 monoclonal antibody in geographic atrophy secondary to age-related macular degeneration","volume":"2","author":"Rosenfeld","year":"2018","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib80","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jop.2010.0109","article-title":"Qualitative spectral OCT\/SLO analysis of drusen change in dry age-related macular degeneration patients treated with Copaxone","volume":"27","author":"Landa","year":"2011","journal-title":"J Ocul Pharm Ther"},{"key":"10.1016\/j.apjo.2026.100305_bib81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajo.2025.03.021","article-title":"Phase 2 study of the anti-high temperature requirement A1 (HtrA1) fab galegenimab (FHTR2163) in geographic atrophy secondary to age-related macular degeneration","volume":"275","author":"Eichenbaum","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100305_bib82","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/13543784.2013.794782","article-title":"Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial","volume":"22","author":"Augustin","year":"2013","journal-title":"Expert Opin Invest Drugs"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib83","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.survophthal.2023.01.007","article-title":"Effects of systemic drugs on the development and progression of age-related macular degeneration","volume":"68","author":"Grimes","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib84","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1167\/iovs.04-1050","article-title":"Reduced foveolar choroidal blood flow in eyes with increasing AMD severity","volume":"46","author":"Grunwald","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"395","key":"10.1016\/j.apjo.2026.100305_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.apjo.2026.100305_bib86","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib87","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100305_bib88","unstructured":"Novartis Pharmaceuticals. A Multicenter, Randomized, Sham-Control, Proof-of-Concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-Related Macular Degeneration. clinicaltrials.gov; 2020. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT01527500\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib89","unstructured":"Alcon Research. A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy. clinicaltrials.gov; 2019. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT02515942\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib90","unstructured":"NGM Biopharmaceuticals, Inc. A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). clinicaltrials.gov; 2025. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04465955\u3009."},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100154","article-title":"A phase I, single ascending dose study of GEM103 (recombinant human complement factor H) in patients with geographic atrophy","volume":"2","author":"Khanani","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"10.1016\/j.apjo.2026.100305_bib92","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/02713683.2022.2053725","article-title":"A novel full-length recombinant human complement factor H (CFH; GEM103) for the treatment of age-related macular degeneration shows similar in vitro functional activity to native CFH","volume":"47","author":"Biggs","year":"2022","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.apjo.2026.100305_bib93","unstructured":"Gemini Therapeutics, Inc. A Multicenter, Open-Label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103. clinicaltrials.gov; 2022. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04643886\u3009."},{"issue":"8","key":"10.1016\/j.apjo.2026.100305_bib94","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/biomedicines10081884","article-title":"Targeting the complement cascade for treatment of dry age-related macular degeneration","volume":"10","author":"Patel","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.apjo.2026.100305_bib95","unstructured":"Apellis Pharmaceuticals, Inc. A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). clinicaltrials.gov; 2023. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03525613\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib96","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ajo.2025.04.016","article-title":"Pegcetacoplan treatment for geographic atrophy in age-related macular degeneration over 36 months: data from OAKS, DERBY, and GALE","volume":"276","author":"Wykoff","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100305_bib97","unstructured":"IVERIC bio, Inc. A Phase 2\/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of ZimuraTM (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. clinicaltrials.gov; 2025. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT02686658\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib98","unstructured":"IVERIC bio, Inc. A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration. clinicaltrials.gov; 2025. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04435366\u3009."},{"issue":"17","key":"10.1016\/j.apjo.2026.100305_bib99","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye"},{"issue":"10411","key":"10.1016\/j.apjo.2026.100305_bib100","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.apjo.2026.100305_bib101","unstructured":"Astellas Pharma Global Development, Inc. An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2). clinicaltrials.gov; 2025. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05536297\u3009."},{"issue":"10411","key":"10.1016\/j.apjo.2026.100305_bib102","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.apjo.2026.100305_bib103","unstructured":"Annexon, Inc. A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) - The ARCHER Study. clinicaltrials.gov; 2024. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04656561\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib104","unstructured":"Annexon, Inc. A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD). clinicaltrials.gov; 2025. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06510816\u3009."},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/imr.13149","article-title":"Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway","volume":"313","author":"Dreismann","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apjo.2026.100305_bib106","unstructured":"Ionis Pharmaceuticals, Inc. A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD). clinicaltrials.gov; 2025. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03815825\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib107","unstructured":"ADARx Pharmaceuticals, Inc. A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). clinicaltrials.gov; 2025. Accessed December 31, 2025. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06990269\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib108","unstructured":"Regeneron Pharmaceuticals. A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration. clinicaltrials.gov; 2025. Accessed December 31, 2025. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06541704\u3009."},{"issue":"17","key":"10.1016\/j.apjo.2026.100305_bib109","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1080\/14656566.2023.2257604","article-title":"The complement system: a novel therapeutic target for age-related macular degeneration","volume":"24","author":"Shughoury","year":"2023","journal-title":"Expert Opin Pharm"},{"key":"10.1016\/j.apjo.2026.100305_bib110","author":"Lai","year":"2025","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100305_bib111","unstructured":"Search ClinicalTrials.gov for: Other terms: NCT06164587 | Card Results | ClinicalTrials.gov. Accessed December 31, 2025. \u3008https:\/\/clinicaltrials.gov\/search?term=NCT06164587\u3009."},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib112","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/jcm11030592","article-title":"Cell Death in AMD: the rationale for targeting Fas","volume":"11","author":"Zacks","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib113","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12974-019-1576-3","article-title":"A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma","volume":"16","author":"Krishnan","year":"2019","journal-title":"J Neuroinflamm"},{"issue":"8","key":"10.1016\/j.apjo.2026.100305_bib114","first-page":"2491","article-title":"Safety and tolerability of intravitreal ONL1204 in patients with macula-off rhegmatogenous retinal detachment","volume":"64","author":"Simunovic","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.apjo.2026.100305_bib115","first-page":"1036","article-title":"Curcumin acts to regress macular drusen volume in dry AMD","volume":"61","author":"Bielskus","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib116","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/ijms26030944","article-title":"Elamipretide: a review of its structure, mechanism of action, and therapeutic potential","volume":"26","author":"Tung","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.apjo.2026.100305_bib117","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/bph.12461","article-title":"First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics","volume":"171","author":"Szeto","year":"2014","journal-title":"Br J Pharm"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100628","article-title":"ReCLAIM-2: A randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation","volume":"5","author":"Ehlers","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib119","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1038\/s41598-025-87921-9","article-title":"Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD)","volume":"15","author":"Lizama","year":"2025","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.apjo.2026.100305_bib120","first-page":"2119","article-title":"Unbiased transcriptomic analysis of the sigma-2 receptor modulator CT1812 in cell-based models of dry age-related macular degeneration","volume":"64","author":"Lizama","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2026.100305_bib121","unstructured":"\u3008https:\/\/fyra.io\u3009. Treating GA: Today and Tomorrow. Retina Today. Accessed December 30, 2025. \u3008https:\/\/retinatoday.com\/articles\/2023-nov-dec\/treating-ga-today-and-tomorrow\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib122","unstructured":"Case Study: Catalyst. Accessed December 31, 2025. \u3008https:\/\/www.mosaicbio.com\/case_1.shtml\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108391","article-title":"Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates","volume":"214","author":"Hughes","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.apjo.2026.100305_bib124","unstructured":"\u3008https:\/\/fyra.io\u3009. Retrotope Reports Positive Results from Studies of RT011 in Animal Models of Retinal Degeneration. Eyewire+. Accessed December 31, 2025. \u3008https:\/\/eyewire.news\/news\/retrotope-reports-positive-results-from-studies-of-rt011-in-animal-models-of-retinal-degeneration\u3009."},{"issue":"8","key":"10.1016\/j.apjo.2026.100305_bib125","first-page":"3771","article-title":"Novel efficacy of bi-specific antibody\/OCUL101 by monthly intravitreal injection in a nonhuman primate blue-light induced phototoxicity model","volume":"66","author":"Chen","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.apjo.2026.100305_bib126","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s40123-024-00982-3","article-title":"Pre-clinical studies of a novel bispecific fusion protein targeting C3b and VEGF in neovascular and nonexudative AMD models","volume":"13","author":"Lee","year":"2024","journal-title":"Ophthalmol Ther"},{"issue":"8","key":"10.1016\/j.apjo.2026.100305_bib127","first-page":"1152","article-title":"Development of a modular IL-1 trap and anti-HTRA1 bispecific for the treatment of dry AMD","volume":"64","author":"Song","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.apjo.2026.100305_bib128","first-page":"197","article-title":"ERM-123 is an orally bioavailable bi-specific RBP4 inhibitor that stabilizes TTR similarly to Tafamidis","volume":"65","author":"McLure","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2026.100305_bib129","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2147\/OPTH.S92359","article-title":"Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects","volume":"9","author":"Danis","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.apjo.2026.100305_bib130","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1097\/IAE.0000000000001283","article-title":"Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration","volume":"36","author":"Sadda","year":"2016","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib131","article-title":"A review of current and future management of geographic atrophy","volume":"6","author":"R S","year":"2017","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib132","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/APO.0000000000000597","article-title":"Microperimetry in retinal diseases","volume":"12","author":"Horie","year":"2023","journal-title":"Asia Pac J Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib133","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.66.3.26","article-title":"Structure-function correlation of deep-learning quantified ellipsoid zone and retinal pigment epithelium loss and microperimetry in geographic atrophy","volume":"66","author":"Birner","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.apjo.2026.100305_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100096","article-title":"Artificial intelligence for retinal diseases","volume":"13","author":"Lim","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100305_bib135","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 Trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100143","article-title":"Triterpenoid saponin-mediated recovery of visual deficits in age-related macular degeneration (AMD): double-blind, placebo-controlled, randomised clinical trial","volume":"14","author":"Lee","year":"2025","journal-title":"Asia Pac J Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100305_bib137","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3928\/23258160-20240430-02","article-title":"Emerging oral pharmaceuticals for dry age-related macular degeneration: mechanism of action, current clinical status, and future directions","volume":"55","author":"DeBoer","year":"2024","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"6","key":"10.1016\/j.apjo.2026.100305_bib138","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3945\/ajcn.2009.27594","article-title":"{omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the age-related eye disease study","volume":"90","author":"Sangiovanni","year":"2009","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib139","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamaophthalmol.2013.7376","article-title":"Secondary analyses of the effects of lutein\/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3","volume":"132","author":"Age-Related Eye Disease Study 2 (AREDS2) Research Group","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100440","article-title":"METformin for the MINimization of geographic atrophy progression (METforMIN): a randomized trial","volume":"4","author":"Shen","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib141","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41421-021-00245-6","article-title":"Identification of an intraocular microbiota","volume":"7","author":"Deng","year":"2021","journal-title":"Cell Discov"},{"key":"10.1016\/j.apjo.2026.100305_bib142","unstructured":"Ingelheim B. Phase II start of oral treatment for Geographic Atrophy. Boehringer Ingelheim. May 6, 2025. Accessed December 17, 2025. \u3008https:\/\/www.boehringer-ingelheim.com\/science-innovation\/human-health-innovation\/phase-ii-start-oral-treatment-geographic-atrophy\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib143","unstructured":"Galimedix Therapeutics Inc. A Phase 2, Double-Masked, Randomized, Multicenter, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of GAL-101, 2%, Ophthalmic Solution in Patients With Non-Foveal Geographic Atrophy Secondary to Non-Neovascular Age-Related Macular Degeneration: eDREAM Study. clinicaltrials.gov; 2025. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06659549\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib144","article-title":"Protective effect of RIPK1-inhibitory compound in in vivo models for retinal degenerative disease","volume":"180","author":"Kh","year":"2019","journal-title":"Exp eye Res"},{"issue":"15","key":"10.1016\/j.apjo.2026.100305_bib145","first-page":"1716","article-title":"Eyedrop application of CLT-005, a Stat3 inhibitor, is efficacious in animal models of wet and dry age-related macular degeneration","volume":"54","author":"Farjo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.apjo.2026.100305_bib146","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2023.12.028","article-title":"Long-term follow-up of a phase 1\/2a clinical trial of a stem cell-derived bioengineered retinal pigment epithelium implant for geographic atrophy","volume":"131","author":"Humayun","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-05611-y","article-title":"Suprachoroidal implantation of corticosteroid slow release implants for the treatment of cystoid macular edema","volume":"15","author":"Asani","year":"2025","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.apjo.2026.100305_bib148","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/02713683.2025.2469829","article-title":"A novel approach for suprachoroidal space injection: an experimental evaluation","volume":"50","author":"Long","year":"2025","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.apjo.2026.100305_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107349","article-title":"Rapid elimination of suprachoroidally injected small molecule drugs into the systemic blood circulation","volume":"215","author":"Laitinen","year":"2025","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.apjo.2026.100305_bib150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/IAE.0000000000003980","article-title":"LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (Dry) age-related macular degeneration using the lumithera valeda light delivery system","volume":"44","author":"Boyer","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2026.100305_bib151","unstructured":"Giannaccare G. Outcomes of Photobiomodulation in DRy Age Related macUlar Degeneration: A proSpective multicEnter raNdomized Controlled (DRUSEN) Study. clinicaltrials.gov; 2024. Accessed January 1, 2026. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06046118\u3009."},{"key":"10.1016\/j.apjo.2026.100305_bib152","article-title":"Subretinal photovoltaic implant to restore vision in geographic atrophy due to AMD","author":"Holz","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apjo.2026.100305_bib153","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ajo.2025.04.022","article-title":"Ocular adverse events associated with pegcetacoplan and avacincaptad pegol for geographic atrophy: a population-based pharmacovigilance study","volume":"276","author":"Kailani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100305_bib154","unstructured":"American Academy of Ophthalmology (AAO). Age-Related Macular Degeneration Preferred Practice Pattern\u00ae 2024. Published February 2025. \u3008https:\/\/www.aao.org\/education\/preferred-practice-pattern\/age-related-macular-degeneration-ppp\u3009."},{"issue":"2","key":"10.1016\/j.apjo.2026.100305_bib155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/APO.0000000000000584","article-title":"Recent advances in clinical applications of imaging in retinal diseases","volume":"12","author":"Szeto","year":"2023","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100305_bib156","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3390\/medicina60060945","article-title":"The complement system as a therapeutic target in retinal disease","volume":"60","author":"Ong","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.apjo.2026.100305_bib157","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/IAE.0000000000000606","article-title":"Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration","volume":"35","author":"Dugel","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2026.100305_bib158","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1167\/iovs.12-9970","article-title":"Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases","volume":"53","author":"Kauper","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2026.100305_bib159","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/IAE.0000000000002632","article-title":"A double-masked, randomized, sham-controlled, single-center study with photobiomodulation for the treatment of dry age-related macular degeneration","volume":"40","author":"Markowitz","year":"2020","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.apjo.2026.100305_bib160","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/APO.0000000000000623","article-title":"Novel drug delivery methods and approaches for the treatment of retinal diseases","volume":"12","author":"Ham","year":"2023","journal-title":"Asia Pac J Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100305_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100090","article-title":"Latest developments of generative artificial intelligence and applications in ophthalmology","volume":"13","author":"Feng","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100305_bib162","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2024-001956","article-title":"Pharmacoproteomics in the development of personalised medicine in Age-related Macular Degeneration (PHARPRO-AMD) study protocol","volume":"10","author":"Ca\u00f1izo-Outeiri\u00f1o","year":"2025","journal-title":"BMJ Open Ophthalmol"},{"issue":"6","key":"10.1016\/j.apjo.2026.100305_bib163","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/jpm13060893","article-title":"Personalized medicine in ophthalmic diseases: challenges and opportunities","volume":"13","author":"Jin","year":"2023","journal-title":"J Pers Med"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:41:09Z","timestamp":1776195669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098926000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":163,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162098926000319"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100305","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel drug development for geographic atrophy","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100305"}}